{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:29:15Z","timestamp":1747193355334,"version":"3.40.5"},"reference-count":8,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Gastroenterol"],"abstract":"<jats:p>Vedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn\u2019s disease and ulcerative colitis who have failed immunomodulator and TNF-\u03b1 antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoencephalopathy. Because it targets gastrointestinal tract-specific lymphocytes, meta-analyses and integrated studies have shown that vedolizumab causes fewer extraintestinal adverse effects, such as opportunistic infections and malignancies, compared with anti-TNF therapies. We present the case of a patient who developed an ovarian teratoma after initiation of vedolizumab therapy.<\/jats:p>","DOI":"10.1159\/000484199","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T22:06:42Z","timestamp":1513894002000},"page":"786-790","source":"Crossref","is-referenced-by-count":1,"title":["Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?"],"prefix":"10.1159","volume":"11","author":[{"given":"Judy\u00a0A.","family":"Trieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1784-212X","authenticated-orcid":false,"given":"Mohammad","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurinder","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.85"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22940"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153973"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315586970"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311079"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13215"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65350-3"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/uog.7610"}],"container-title":["Case Reports in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/484199","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/484199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:08:57Z","timestamp":1745428137000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000484199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":8,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,1,12]]}},"URL":"https:\/\/doi.org\/10.1159\/000484199","archive":["Portico"],"relation":{},"ISSN":["1662-0631"],"issn-type":[{"type":"electronic","value":"1662-0631"}],"subject":[],"published":{"date-parts":[[2017,12,21]]}}}